Gossamer Bio (GOSS) Operating Expenses (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Operating Expenses of $61.8 million for Q1 2026, up 32.38% year-over-year from $46.7 million in Q1 2025, and up 3.31% quarter-over-quarter from $59.8 million in Q4 2025.
Gossamer Bio (GOSS) Operating Expenses (2018 - 2026) Analysis & Trends
Gossamer Bio's Operating Expenses history runs 9 years deep, the most recent figure standing at $61.8 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 32.38% year-over-year to $61.8 million; the TTM figure through Mar 2026 stood at $234.3 million (up 30.64% YoY), while the FY2025 annual figure was $219.2 million, up 25.53% from the prior year.
- Operating Expenses for Q1 2026 stood at $61.8 million, up from $59.8 million in the prior quarter.
- The five-year high for Operating Expenses was $62.4 million in Q3 2025, with the low at $40.5 million in Q3 2023.
- The 5-year median for Operating Expenses is $49.0 million (2023), against an average of $50.5 million.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses fell 27.72% in 2023, then soared 43.8% in 2025.
- Gossamer Bio's Operating Expenses stood at $54.4 million in 2022, then declined by 9.81% to $49.0 million in 2023, then dropped by 7.18% to $45.5 million in 2024, then jumped by 31.49% to $59.8 million in 2025, then climbed by 3.31% to $61.8 million in 2026.
- Business Quant data shows GOSS's Operating Expenses at $61.8 million in Q1 2026, $59.8 million in Q4 2025, and $62.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | 35.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.31 Mn |
| Mar 31, 2026 | 61.82 Mn |
| Dec 31, 2025 | 59.84 Mn |
| Sep 30, 2025 | 62.41 Mn |
| Jun 30, 2025 | 50.25 Mn |
| Mar 31, 2025 | 46.70 Mn |
| Dec 31, 2024 | 45.51 Mn |
| Sep 30, 2024 | 43.40 Mn |
| Jun 30, 2024 | 43.76 Mn |
| Mar 31, 2024 | 41.96 Mn |
| Dec 31, 2023 | 49.03 Mn |
| Sep 30, 2023 | 40.49 Mn |
| Jun 30, 2023 | 46.30 Mn |
| Mar 31, 2023 | 47.94 Mn |
| Dec 31, 2022 | 54.36 Mn |
| Sep 30, 2022 | 56.02 Mn |
| Jun 30, 2022 | 53.87 Mn |
| Mar 31, 2022 | 54.34 Mn |
| Dec 31, 2021 | 51.66 Mn |
| Sep 30, 2021 | 55.66 Mn |